免疫检查点抑制剂在多发性骨髓瘤中的过去,现在和未来

Valeria Tomarchio1, Anna Crescenzi2, Mariantonietta Tafuri1

  • 1Operative Research Unit of Hematology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.

Expert review of hematology
|February 23, 2025
PubMed
概括

免疫检查点抑制剂 (ICI) 在治疗多发性骨髓瘤方面表现有前途,特别是与CAR-T细胞或双特异性抗体结合使用时. 这种组合可以克服耐药性并改善患者的治疗结果.

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K